TrialBlood advances2019

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.

Benjamin L Lampson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.